NEW YORK (GenomeWeb) — Chinese startup Cure Genetics announced today that it has raised $17 million in a Series A financing round.
The round was led by Qiming Venture Partners and included investments from CTS Capital and Ascendin Investment.
Cure Genetics was founded in 2016 to develop medicines and molecular diagnostics based on its gene editing and delivery technologies. The company said it intends to use the financing to further optimize its technology platforms, to sponsor regulatory filings and clinical trials, and to expand its pipeline.